DHR — DANAHER CORP /DE/

—
NYSE · Unknown · Unknown · CIK 313616 ·
Last close
$225.77
Market Cap
$158.71B
52W High
$241.35
52W Low
$160.31
ADV30
4,137,088
Next earnings
2027-01-27

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 6,554,000,000 3,837,000,000 1,245,000,000 1,235,000,000 93,281,000,000 5,682,000,000 39,648,000,000
Jun 2026 6,265,000,000 3,611,000,000 1,127,000,000 870,000,000 92,367,000,000 4,348,000,000 39,775,000,000
Mar 2026 5,951,000,000 3,591,000,000 1,344,000,000 1,029,000,000 83,544,000,000 5,701,000,000 30,587,000,000
Dec 2025 6,838,000,000 3,966,000,000 1,502,000,000 1,197,000,000 83,464,000,000 4,615,000,000 30,923,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$6,635,000,000
Investing CF
$-11,092,000,000
Financing CF
$5,860,000,000
CapEx
$-1,169,000,000
Dividends Paid
$-964,000,000
Buybacks
$-2,904,000,000
EPS Diluted TTM
$5.63
As of
2026-10-25

Balance + Analyst (yfinance extras)

Retained Earnings
$48,226,000,000
Inventory
$3,260,000,000
Receivables
$3,965,000,000
ST Investments
—
EBIT TTM
$5,054,000,000
Pretax Income TTM
$4,762,000,000
Interest Exp TTM
$292,000,000
Analysts
21

Yahoo Snapshot (yfinance, live)

Total Revenue
$25,607,999,488
EBITDA
$8,256,000,000
Free Cash Flow
$4,746,250,240
Enterprise Value
$184,275,845,120
Total Cash
$5,681,999,872
Total Debt
$27,782,000,640
Shares Out
702,986,054
Trailing EPS
$6.04
Book Value
$76.23
ROE
8.2%
ROA
4.1%
Div Yield
0.69%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 24,568,000,000 4,690,000,000 3,614,000,000 83,464,000,000 30,923,000,000 52,534,000,000 6,416,000,000
Dec 2024 23,875,000,000 4,863,000,000 3,899,000,000 77,542,000,000 27,992,000,000 49,543,000,000 6,688,000,000
Dec 2023 23,890,000,000 5,202,000,000 4,764,000,000 84,488,000,000 30,998,000,000 53,486,000,000 7,164,000,000
Dec 2022 26,643,000,000 7,536,000,000 7,209,000,000 84,350,000,000 34,260,000,000 50,082,000,000 8,519,000,000

TTM Snapshot

Revenues TTM
$25,107,000,000
NetIncome TTM
$4,004,000,000
OpCashFlow TTM
—
Assets (Latest)
$92,367,000,000
Forward EPS
$9.31

Max Pain — expiry 2026-11-27 (volume-derived — Yahoo OI feed degraded)

max pain strike: $225.00 · spot: $228.58 · call volume: 520 · put volume: 283

Peers — same industry

TickerNameMarket CapLastDaily %
LMT LOCKHEED MARTIN CORP $136.37B $590.34 —
KLAC KLA CORP $188.36B $144.56 —
SPOT Spotify Technology S.A. $123.76B $602.01 —
SMERY Siemens Energy AG/ADR $118.10B $27.76 —
IBM INTERNATIONAL BUSINESS MACHINES CORP $218.41B $231.09 —

News headlines (Yahoo Finance, 1h cache)

FDA clears Masimo’s brain function monitor
2026-11-19 09:31 · Yahoo
Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Push
2026-11-18 08:12 · Yahoo
Global Point of Care (POC) Immunoassay Analyzer Expansion Market 2026 | Capture 8.8% CAGR to 2030 as Roche, Abbott, Siemens Healthineers and Danaher Scale AI-Enabled POC Testing
2026-11-16 15:27 · Yahoo
Danaher (DHR) Is A Key Supplier In Fast Growing Bioprocessing Markets
2026-11-12 19:09 · Yahoo
A Memo To Danaher's Biotechnology Team About Turning Orders Into Sales
2026-11-12 15:13 · Yahoo
Microfluidic Device Systems - Global Strategic Business Report 2026: Capitalize on 8.7% CAGR to $11.1 Billion by 2032 | Abbott, Danaher, Bio-Rad, and Siemens Healthineers Shape the Competition
2026-11-12 14:57 · Yahoo
Tangential Flow Filtration - Global Strategic Business Report 2026: Capitalize on a $2B Revenue Shift to $3.6B by 2032 as Danaher, MilliporeSigma, GE Healthcare, and Alfa Laval Accelerate Competition
2026-11-12 14:56 · Yahoo
Single-Use Bioprocessing - Global Strategic Business Report 2026: Capitalize on 13.4% CAGR to $47.7B by 2032, Featuring Profiles of Danaher, Thermo Fisher Scientific, 3M, and Eppendorf
2026-11-12 14:54 · Yahoo
Danaher’s Cepheid business to lay off 67 people in California
2026-11-11 15:57 · Yahoo
Global Biotechnology Market to Reach $5 Trillion by 2032, Driven by Biopharmaceuticals, Gene Editing and Sustainable Innovation | Features Profiles of Danaher, Roche, Illumina, Merck, Thermo Fisher an
2026-11-11 14:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.